Jaime Chu, MD Email Jaime Chu
-
- Position
- ASSISTANT PROFESSOR | Pediatrics, Hepatology
-
- Specialties
- Pediatrics
- Liver Transplantation
- Pediatric Hepatology
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- Faculty Practice Associates 212-659-8060 212-659-8060
-
Faculty Practice Associates
5 East 98th Street, 10th Floor
New York, NY 10029
Phone: 212-659-8060212-659-8060
Dr. Jaime Chu is an Assistant Professor of Pediatrics in the Division of Pediatric Hepatology at the Mount Sinai Kravis Children’s Hospital and Mount Sinai’s Recanati/Miller Transplantation Institute. She received her B.A. magna cum laude from Harvard University and her M.D. from New York University School of Medicine. She completed her General Pediatrics residency training at Children’s Memorial Hospital at Northwestern University in Chicago, IL and her fellowship in Pediatric Gastroenterology, Hepatology, and Nutrition both at Children’s Memorial Hospital and at the Mount Sinai School of Medicine.
Certification
Pediatric Gastroenterology
Clinical Focus
- Acute and Chronic Liver Failure
- Autoimmune Hepatitis
- Biliary atresia
- Liver Transplant
- Metabolic liver disease
- Nonalcoholic fatty liver disease
- Portal Hypertension
Education
MD, New York University School of Medicine
BA, Harvard University
MD, New York University School of Medicine
Residency, Pediatrics
Children's Memorial Hospital
Fellowship, Pediatric Gastroenterology
Children's Memorial Hospital
Fellowship, Pediatric Gastroenterology
Mount Sinai School of Medicine
Language
English
Glycosylation and Cancer Metabolism
Dr. Chu is both a clinician and an NIH-funded physician-scientist, leading a research team investigating the intersection of glycosylation and cancer metabolism with special focus on congenital disorders of glycosylation (CDG).
CDG are rare—only an estimated 1,000 patients identified worldwide—and underdiagnosed genetic disorders. Children born with CDG have discrete defects in the processes that are essential for protein secretion and function, and present with debilitating, multisystemic disease. These patients develop signs of common liver and gastrointestinal diseases, making the study of CDG particularly relevant to the broader field of liver disease, as steatosis, fibrosis, and cirrhosis have all been associated with defects in protein glycosylation.
Dr. Chu has been the recipient of several National Institutes of Health (NIH) grants (T32, K12), including a Mentored Clinical Scientist Development Award (K08) to further examine the role of p53 in CDG. Previously, Dr. Chu, with Kirsten Sadler Edepli, PhD, Associate Professor of Medicine (Liver Diseases), and Developmental and Regenerative Biology, has participated in a national consortium funded by an NIH American Recovery and Reinvestment Act grant, and were the first to establish zebrafish as a model to study CDG. Currently, Dr. Chu has been awarded the Gilead Liver Research Scholars in Liver Disease to study the metabolic regulation of liver fibrosis. In addition, Dr. Chu has been awarded the Art in Giving/Rachel Molly Markoff Foundation Research Award to study the role of mannose metabolism in childhood brain cancer.
Dr. Chu is also a member of The Mindich Child Health and Development Institute, the translational research enterprise that works closely with the Department of Pediatrics, to advance knowledge and therapies for pediatric diseases.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Chu did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.